Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are small-molecule therapies that inhibit the intracellular tyrosine kinase activity of the EGFR (EGFR, also known as ERBB1).
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are small-molecule therapies that inhibit the intracellular tyrosine kinase activity of the EGFR (EGFR, also known as ERBB1). EGFR activation normally promotes receptor phosphorylation and downstream signaling through pathways such as RAS–RAF–MEK–ERK and PI3K–Protein kinase B (PKB), which regulate cell proliferation, survival, migration, and differentiation. By occupying the receptor’s ATP-binding pocket, EGFR-TKIs reduce EGFR autophosphorylation and can suppress growth of tumors dependent on EGFR signaling.
EGFR-TKIs have particular clinical and experimental importance in molecularly selected non-small-cell lung cancer (NSCLC), especially tumors containing activating EGFR alterations. Commonly studied agents include gefitinib and erlotinib, while later-generation inhibitors have been developed to address selected resistance mechanisms. Their activity can be influenced by tumor genotype, EGFR amplification, pathway reactivation, and acquired resistance. EGFR-TKI treatment is also associated with characteristic adverse effects, including skin rash; however, the clinical interpretation of rash as a marker of treatment benefit requires careful consideration of time-dependent biases. EGFR-TKIs are additionally investigated in combination with other targeted therapies, including KRAS G12C inhibitors, anti-EGFR antibodies, antibody–drug conjugates, antiangiogenic agents such as bevacizumab, and strategies targeting autophagy or ferroptosis.
Rebuilt from PubMed 10 Sept 2026 · no new papers today
Where the papers sit
8 papers study epidermal growth factor receptor tyrosine kinase inhibitors directly. Those 8 are one subject: EGFR-Targeted Cancer Therapy. EGFR-targeted therapy is examined across NSCLC, squamous-cell tumoroids and experimental kinase inhibitors. Recurring questions are early progression, drug tolerance and resistance, alongside skin toxicity and candidate compounds that block EGFR signaling. No way of splitting those 8 scores better than chance. 1 paradigm shift and 1 new direction follow.
EGFR amplification or mutation does not by itself make EGFR-TKI monotherapy an adequate treatment
The EGFR-amplified carcinoma of unknown primary tumoroid and xenograft model showed only modest growth suppression with EGFR tyrosine kinase inhibition, whereas an EGFR-targeted antibody-drug conjugate produced the strongest inhibition 42616271Aug; independently, the osimertinib-treated EGFR-mutant non-small cell lung cancer drug-tolerant-persister model showed that ULK1 inhibition could delay the emergence of EGFR-TKI tolerance 42407241Jul. Together, these findings replace the assumption that an EGFR-amplified or EGFR-mutant model is adequately addressed by EGFR-TKI treatment alone with a model in which treatment durability or efficacy requires a distinct therapeutic strategy, such as antibody-drug conjugation or targeted suppression of tolerance.
EGFR-TKIs can be deployed to overcome resistance to KRAS G12C inhibitors
The patient-derived xenograft, mouse, and leptomeningeal-carcinomatosis models of KRAS G12C-mutant non-small cell lung cancer identified autocrine amphiregulin-driven EGFR activation as a mechanism of intrinsic and acquired KRAS G12C-inhibitor resistance, and found that combining KRAS inhibitors with EGFR-TKIs suppressed tumor growth 42393288Jul. This assigns EGFR-TKIs a role not centered on treating an EGFR-driven tumor, but on blocking an EGFR-mediated escape pathway in KRAS-mutant disease, including central nervous system metastatic recurrence.
Recent Findings on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Recent work converges on the view that response to epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs) in lung cancer is heterogeneous and shaped by both baseline disease features and adaptive tolerance. In EGFR-mutant non-small cell lung cancer, early progression was independently associated with smoking, lower body mass index, greater tumor burden, liver or bone metastases, pleural effusion, later-line treatment, first-generation EGFR-TKI exposure, and Mesenchymal-Epithelial Transition Factor amplification, supporting risk-adapted monitoring 42536589Jul. Complementing this clinical risk stratification, preclinical models implicate ULK1-dependent autophagy in the emergence of osimertinib-tolerant persister cells; pharmacological or genetic ULK1 inhibition prevented tolerance and enhanced osimertinib activity, although its effect after established tolerance or resistance was modest 42407241Jul. The prognostic significance of EGFR-TKI-associated skin rash is being reassessed using methods that account for immortal time bias, but the available abstract does not report the resulting mortality estimate 42381293Jul. In parallel, computationally supported screening identified nogalamycin derivatives with stronger in-vitro antiproliferative and EGFR-kinase inhibitory activity than comparator agents, indicating a movement toward biomarker-informed monitoring, tolerance-directed combinations, and new chemical inhibitor scaffolds 42336028Jun.
The EGFR-amplification and resistance studies emphasize that EGFR dependence and therapeutic sensitivity are context-specific rather than uniform. In an EGFR-amplified carcinoma of unknown primary, EGFR-TKI treatment produced only modest growth suppression, whereas anti-EGFR antibodies had moderate activity and an EGFR-targeted antibody-drug conjugate produced the greatest inhibition, with tumoroid sensitivity broadly reflecting the patient’s clinical response to platinum chemotherapy plus necitumumab 42616271Aug. Conversely, in KRAS G12C-mutant non-small cell lung cancer, amphiregulin-driven EGFR phosphorylation contributed to both intrinsic and acquired resistance to KRAS G12C inhibitors, and combined EGFR-TKI/KRAS inhibition suppressed resistant tumors, including in a leptomeningeal carcinomatosis model; these findings support functional models and biomarker-guided combinations rather than assuming that EGFR amplification or activation predicts uniform sensitivity to EGFR-TKIs 42393288Jul.
Early inhibitor-discovery work using Moringa oleifera pericarp has identified a semi-synthetic glycosylated enone, S2M2, as a dual-target lead against EGFR tyrosine kinase and carbonic anhydrase IX. S2M2 showed the strongest cytotoxic activity among the tested compounds in HepG2 and HCT116 cells, favorable selectivity toward cancer cells over WI-38 fibroblasts, and potent inhibition of both targets, while molecular docking, molecular dynamics simulations, and MM-GBSA calculations supported stable and energetically favorable binding 42401652Jul. The proposed structure–activity relationship assigns an important role to the α,β-unsaturated carbonyl moiety, positioning S2M2 and related sugar-based phenolic scaffolds for further preclinical evaluation rather than clinical use.
Written from 8 PubMed abstracts, each one cited by PMID above. Published: 2026-08-23. Last written: 2026-08-27 by GPT. Drafted by language models from published abstracts; not medical advice.